Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1974 Nov;10(5):1003-9.
doi: 10.1128/iai.10.5.1003-1009.1974.

Immunological studies of anergic patients

Affiliations

Immunological studies of anergic patients

D E Van Epps et al. Infect Immun. 1974 Nov.

Abstract

Sixty-one patients with a variety of different illnesses were studied with respect to skin test anergy and the presence of serum chemotactic inhibitors. In initial testing, 55% of the patient tests demonstrated negative skin test responses to all six test antigens. Sera from 65% of these anergic patients were capable of suppressing the migration of normal polymorphonuclear leukocytes toward chemotactic factors. Statistical analysis of the association of anergy and chemotactic inhibitory sera resulted in a P value of <0.0005. Chemotactic inhibitory sera were also capable of suppressing monocyte chemotaxis. No association of chemotactic inhibitory activity and lymphocytotoxic antibody or suppressors of mitogen-induced lymphocyte blast transformation were noted. In addition, T-cell populations in some anergic patients were studied by the erythrocyte-binding technique. Erythrocyte-binding lymphocytes in anergic patients were significantly suppressed when compared to normal controls, but not when compared to skin test-positive patients. The data presented here indicate a close parallel between skin test anergy and the presence of serum chemotactic inhibitory activity. The exact relationship is yet undefined but may indicate the involvement of chemotactic inhibitors as immunological regulators in the host during a variety of systemic illnesses.

PubMed Disclaimer

References

    1. J Exp Med. 1972 Aug 1;136(2):207-15 - PubMed
    1. J Immunol. 1972 Jan;108(1):81-5 - PubMed
    1. Am J Dig Dis. 1971 Jun;16(6):509-16 - PubMed
    1. Scand J Immunol. 1972;1(3):269-80 - PubMed
    1. Am J Med. 1972 Jan;52(1):63-72 - PubMed